Starboard joins opposition to Bristol-Myers’ $74 billion Celgene deal

(Reuters) – Activist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co’s second-largest investor, Wellington Management, in opposing the drugmaker’s $74 billion purchase of biotech Celgene Corp on Thursday, sowing further doubt on what would be the largest pharmaceutical takeover ever. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured…

Continue reading